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Abstract
Peritoneal dialysis (PD) is a viable but under-prescribed treatment for uremic patients. Concerns about its use include the 
bio-incompatibility of PD fluids, due to their potential for altering the functional and anatomical integrity of the peritoneal 
membrane. Many of these effects are thought to be due to the high glucose content of these solutions, with attendant issues 
of products generated during heat treatment of glucose-containing solutions. Moreover, excessive intraperitoneal absorp-
tion of glucose from the dialysate has many potential systemic metabolic effects. This article reviews the efforts to develop 
alternative PD solutions that obviate some of these side effects, through the replacement of part of their glucose content 
with other osmolytes which are at least as efficient in removing fluids as glucose, but less impactful on patient metabolism. 
In particular, we will summarize clinical studies on the use of alternative osmotic ingredients that are commercially avail-
able (icodextrin and amino acids) and preclinical studies on alternative solutions under development (taurine, polyglycerol, 
carnitine and xylitol). In addition to the expected benefit of a glucose-sparing approach, we describe an ‘osmo-metabolic’ 
approach in formulating novel PD solutions, in which there is the possibility of exploiting the pharmaco-metabolic properties 
of some of the osmolytes to attenuate the systemic side effects due to glucose. This approach has the potential to ameliorate 
pre-existing co-morbidities, including insulin resistance and type-2 diabetes, which have a high prevalence in the dialysis 
population, including in PD patients.
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Introduction
Peritoneal Dialysis (PD) is an established home care, cost-
effective kidney replacement therapy, which compared to 
hemodialysis (HD), offers several advantages including 
better preservation of residual renal function, a more gradual 
and continuous solute and fluid clearance, minimal cardiac 
stress, and similar survival [1]. Several studies over the last 
decade also show that PD may be a safe and efficient alterna-
tive to HD in late-presenting ESRD patients requiring urgent 
start of dialysis [2]. The dialysate composition includes 
physiological concentrations of chloride, calcium, sodium, 
magnesium, and a buffer (lactate and/or bicarbonate). It is 
also necessary to add an osmotic agent to the solution which 
will induce water flow, and thereby ultrafiltration, across 
the peritoneal capillaries via both the water-exclusive aqua-
porin and the small-pore, solute-coupled fluid pathways [3]. 
Glucose (molecular weight 180 Da) is the standard osmotic 
agent used, with concentrations 10-to 50-fold higher than 
physiological levels [4].
Despite potential benefits, PD is prescribed to only a 
minority of dialysis patients in certain countries and regions, 
about 10% in the USA and 13% in Europe [1, 5]. Infectious 
complications (primarily peritonitis) and catheter problems 
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are the main contributors to reduced technique survival in 
the short and mid-term. For patients on long term PD, bio-
incompatibility of dialysate may represent the main prob-
lem. Biocompatibility of a PD solution can be defined as 
its capacity to leave the anatomical and functional natural 
characteristics unmodified in time; and it can be divided into 
local (peritoneum cavity) and systemic. Indeed, it is gener-
ally accepted that conventional PD fluids alter the functional 
and anatomical integrity of the peritoneal membrane over 
time, by causing inflammation, neoangiogenesis and fibrosis 
[6]. The progressive damage to the peritoneal membrane is 
evidenced by faster peritoneal solute transport rate and by 
a decline of UF capacity eventually resulting in UF failure, 
which is often characterized by impaired osmotic conduct-
ance [7]. More widespread usage of standard dialysate would 
involve more long-term patients at risk of these problems. 
Some patients may also develop encapsulating peritoneal 
sclerosis, a rare but serious complication [8].
Several potential factors have been claimed to be respon-
sible for the poor biocompatibility of PD solutions, includ-
ing elevated levels of glucose degradation products (GDPs) 
generated during heat-sterilization of glucose-based solu-
tions, hyperosmolarity, lactate buffer, low pH, and high 
glucose exposure [9]. In an effort to improve PD, newer, 
so called biocompatible glucose-based dialysis solutions 
characterized by neutral or physiological-pH and low-GDP 
fluids using multi-chamber bags, have been introduced into 
the market [10] as well as by using other osmotic agents 
(icodextrin, amino acids) and thereby decreasing the level 
of glucose exposure. The clinical value of some of the new 
glucose-based PD solutions, which contain as much glucose 
as standard solutions, is however still uncertain [11]. PD 
patients treated with these solutions may experience impor-
tant benefits such as better preservation of urine volume and 
kidney function [12], but also a tendency to overhydration 
likely due to diminished ultrafiltration [13]. In a recent study, 
Elphick et al. [14] found that use of biocompatible solutions 
was associated with a slow but progressive rise of peritoneal 
solute transport rate, which reached levels comparable to 
those seen with standard dialysate after two years of treat-
ment and thereafter plateaued (while continuing to increase 
with standard solutions), a potentially beneficial effect that 
deserves further investigation. Moreover, based on recent 
findings [15], biocompatibility of neutral -pH, low-GDP 
fluids cannot be assumed [16]. In children on PD, use of 
such dialysate was in fact found to induce early peritoneal 
inflammation, fibroblast activation, epithelial-mesenchymal 
transition and marked angiogenesis, which determined the 
PD membrane transport function [15].
Thus, since glucose is the common denominator in the 
conventional and low-GDP PD solutions, glucose per se, 
as originally thought, might be the main culprit behind 
adverse events occurring locally and systemically during 
the PD lifetime of a patient. Depending mostly on the 
dialysate volume and glucose concentration used, but also 
to some extent the peritoneal membrane transport status, 
PD patients can absorb up to 200 g of glucose per day [17]. 
Glucose absorption may play a distinct role in the longitu-
dinal changes to the structure and function of the peritoneal 
membrane observed in some patients [18]. For example, in 
keeping with the relevance of sodium removal/balance in PD 
patients, preserving the integrity of the peritoneal membrane 
function would be key to guarantee an adequate dialytic 
sodium removal particularly in APD patients [19, 20], and to 
achieve a better control of volemia and blood pressure [21]. 
Moreover, excessive intraperitoneal absorption of glucose 
from the dialysate has many potential systemic metabolic 
effects, including insulin resistance, new onset diabetes, and 
cardiovascular disease, which can be attributed to a combi-
nation of the effects of carbohydrate and caloric uptake, as 
well as hyperglycemia [17, 22]. A counter argument could 
be represented by the obesity paradox, since several epide-
miological cohorts have demonstrated that higher body mass 
index is associated with a reduced mortality risk in patients 
on chronic hemodialysis [23]. However, no apparent associa-
tion between obesity and mortality was consistently found 
for PD patients [24]. One possible reason for this is the pres-
ence of glucose in the dialysate, providing regular caloric 
supplementation that may offset the nutritional advantage 
of adipose stores to draw on.
Strategies devised to reduce/eliminate glucose-associated 
toxicity (glucose sparing), represent one of the key objec-
tives of present-day research in PD. In this article, we (i) 
review the evidence for substances used as alternative 
osmotic agents to glucose for PD, and (ii) detail the ration-
ale and the results obtained so far for the novel proposed 
osmo-metabolic approach to the composition of new PD 
solution [25].
PD solutions with an alternative osmotic 
agent
Commercially available PD solutions
Several alternatives to glucose were examined over the 
years, but only two agents are currently used in glucose-
free dialysate: icodextrin and amino acids. It should be noted 
that both solutions only replace up to 50% of daily glucose 
absorption [22].
The colloidal osmotic agent icodextrin is a water-soluble 
glucose polymer derived from starch, which allows for a 
slow but sustained peritoneal ultrafiltration and is indi-
cated for use during a single long dwell per day [26]. It 
is of particular value in high solute transport patients and 
improves patient’s ultrafiltration without increased risk of 
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adverse effects [27, 28]. Evidence of its benefit on glucose 
metabolism has been reported in three randomized clinical 
trials; two in diabetic CAPD [29, 30] and one in non-diabetic 
APD [31] patients. Both studies with diabetic patients used 
changes in glycated haemoglobin (HbA1C) as a primary 
endpoint, and in both studies, a significant reduction in 
the levels of HbA1C at the end of follow-up was observed. 
On the other hand, the study of non-diabetic APD patients 
showed that the use of icodextrin during the long dwell for 
non-diabetic patients in APD improves insulin resistance by 
HOMA index, reducing exposure to glucose PD solutions 
[31].
The clinical benefits of icodextrin appear to stem from 
better fluid removal as well as of its glucose sparing prop-
erty. There are several studies suggesting that long-term 
utilization of icodextrin solution may extend patient and 
technique survival in PD [32–34]. A very recent system-
atic review and meta-analysis examined the efficacy and 
safety of icodextrin versus glucose-only PD regimens [35]. 
Data analyzed were from 19 randomized controlled trials, 
enriched with unpublished data from investigator-initiated 
and industry-sponsored studies. Icodextrin-containing PD 
solution proved to be associated with clear fluid benefits, 
such as improvement of peritoneal ultrafiltration and fewer 
episodes of fluid overload (both with high certainty of evi-
dence). As a matter of fact, icodextrin has been used as a sal-
vage therapy in PD patients with refractory volume overload 
who were otherwise about to be transferred to HD [36, 37].
The use of icodextrin as a PD fluid may extend time on 
PD treatment. It is anticipated, therefore, that the share of 
patients treated with PD will be positively influenced. The 
relationship between extension of PD treatment time and 
an increase of the PD treatment share, however, is complex 
and has been investigated by [38] utilizing the Markov chain 
model to forecast changes in the development of the ESRD 
program over time. They concluded that the direct and indi-
rect effects of extended time on PD treatment result in cost 
savings that could amount to 1.0% of the total cost of dialy-
sis treatment in The Netherlands. Although the relative cost 
savings are low, the absolute cost savings are substantial. 
These cost savings would make it possible to offer dialy-
sis treatment to more patients with equal budgets. In The 
Netherlands, the cost savings would allow for 452 more HD 
patient years or 635 more PD patient years in the 10-year 
model period.
However, further high quality, adequately powered ran-
domized clinical trials of sufficient duration are required to 
accurately establish whether the use of icodextrin solution 
helps patients to stay on PD longer or live longer [12].
Amino acid based PD solutions (e.g. Nutrineal®) offer the 
possibility of improving the poor nutritional status of some 
patients. However, due to the risk of acidosis and azotemia, 
their use has to be limited to one peritoneal exchange per 
day [39]. Nutrineal® is a glucose- and GDP-free amino 
acid-based (0.1%) solution. Accordingly, long-term use 
(3 years) resulted in normalized protein nitrogen in the 
bodies of patients. This was accompanied by a decrease in 
plasma triglycerides [40, 41] and phosphate levels [41–43]. 
Other studies [44–46] have shown that Nutrineal® is a more 
biocompatible PD solution than glucose-based ones. Specifi-
cally, Asola et al. [47] have shown (using  [11C]methylami-
noisobutyrate -based PET) that muscle amino acid uptake 
is markedly increased when patients are treated with 1.1% 
amino acid PD solutions. Delarue et al. [48] further showed 
that simultaneous carbohydrate intake by patients receiv-
ing Nutrineal® PD treatment have a more positive nitrogen 
balance, indicating that the timing of a once-a-day amino 
acid based PD infusion relative to the patient’s main meal is 
important. Canepa et al. [49] used a combined glucose–ami-
noacid PD solution for 6 months in 8 pediatric APD patients. 
They found an improvement of anthropometric parameters, 
particularly those indicating muscle mass and fat stores 
without modifications of nitrogen waste products were 
observed. Subsequently Canepa et al. [50] reported a further 
study using an automatic PD cycler to infuse glucose and 
AA solutions (proportion of 3:1) simultaneously in pediatric 
PD patients during the night [50]. This resulted in favorable 
effects on protein synthesis, hyperinsulinemia, prevention 
of hyperaminoacidemia, and on maintenance of adequate 
non-protein calorie/nitrogen ratio (115.4:1) of the absorbed 
glucose and AA. Therefore, these findings supported the use 
of this combined glucose-aminoacid solutions, to improve 
utilization of AA for protein synthesis while controlling 
BUN levels [50]. However, it would be of interest to ascer-
tain whether the exposure to combined glucose and amino 
acid solutions is appropriate for PD patients who are already 
insulin resistant or overtly diabetic, owing to the gluconeo-
genic potential of the amino acids.
To evaluate whether changes in substrate and insulin 
levels that occur during PD have effects on muscle protein 
dynamics by studying muscle protein synthesis, breakdown, 
and net balance, a crossover study in which adult PD patients 
served as their own controls was performed by Garibotto 
et al. [51]. The forearm perfusion studies associated with 
the kinetics of 3 H-phenylalanine were performed (1) in the 
basal state and during PD with dialysates that contained 
dextrose alone in different concentrations, (2) during PD 
with dialysates containing dextrose alone or dextrose and 
AA, and (3) in time controls. This study indicated that in 
PD patients in the fasting state, the moderate hyperinsuline-
mia that occurs during PD with dextrose alone causes an 
anti-proteolytic action that is obscured by a parallel decrease 
in AA availability for protein synthesis. Conversely, the 
combined use of dextrose and AA results in a cumulative 
effect, because of the suppression of endogenous muscle 
protein breakdown (induced by insulin) and the stimulation 
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of muscle protein synthesis (induced by AA availability). 
When patients on PD are in a fasting state or in a condition 
with reduced nutrient intake, muscle mass might be main-
tained better by the combined use of glucose and AA (sup-
pression of protein breakdown and stimulation of muscle 
protein synthesis) [52].
Recently, Tjiong et al. [42] in a single, open label, random 
order crossover study, compared the effects of a mixture of 
AA and glucose versus glucose only containing dialysate, 
in 2 periods of 7 days each in eight APD patients. They 
concluded that CCPD with dialysate composed of a mixture 
of AA and glucose acutely improves protein metabolism, 
and that this gain made during the night persists to a con-
siderable extent for 24 h. This may be promising for long-
term improvement of nutritional status in selected groups 
of patients.
Potential benefits of glucose-sparing by above formu-
lations have been reported [22]. More recently, two rand-
omized studies (IMPENDIA, EDEN) evaluated whether 
a low-glucose regimen improves metabolic control in dia-
betic patients on PD [30]. Patients were randomized 1:1 to 
dextrose solutions only (control group) or to a low-glucose 
strategy (combination of icodextrin, amino acids, and 
dextrose-based solutions in IMPENDIA; the same but for 
a different dextrose-based solution in EDEN trial). After 
6 months, mean glycated hemoglobin (primary end-point) 
improved in the intervention group (0.5% difference between 
groups, p = 0.006). The study also demonstrated modest but 
significant improvements in several lipid measures, includ-
ing triglycerides, VLDL, and apolipoprotein B, in the glu-
cose-sparing group; these improvements could conceivably 
reduce atherosclerotic risk in the longer term, though this 
potential benefit requires an outcome study. However, the 
authors reported in the intervention group a greater num-
ber of deaths and serious adverse events, including several 
related to extracellular fluid volume expansion [30]. A pos-
sible explanation, also expressed by the authors, is that in the 
pursuit of better metabolic values, investigators used lower 
concentrations of dextrose-based dialysis fluid, when more 
hypertonic dialysate was indicated to optimize ultrafiltra-
tion. If this were the case, the investigators may not have 
recognized the association between reduced ultrafiltration 
and these adverse events. It follows, then, that a preference 
for less hypertonic dialysate could have contributed to the 
improved metabolic results seen in the intervention group.
The results of these studies, besides confirming improve-
ments in metabolic control of a glucose-sparing prescrip-
tion as evidenced by reductions in  HbA1c, serum VLDL 
cholesterol, serum triglycerides, and apolipoprotein B, 
also emphasize the importance of efficacious ultrafiltration 
and the need for close monitoring of fluid status with any 
glucose-sparing strategy. Furthermore, the wealth of data, 
information and experience published with glucose-sparing 
PD solutions (icodextrin, amino acids) already in the market, 
strongly indicate that the need for new osmotic agents target-
ing its effect not only on biocompatibility and fluid balance, 
but also and equally important, on metabolism, is of utmost 
importance for the future of PD.
PD solutions under development
Experience over the last three decades has shown that the 
development of effective and safe osmotic agents to be used 
in PD solutions undoubtedly proves challenging. For exam-
ple, small-molecular-weight candidates (like members of 
sugar alcohol or monosaccharide or disaccharide families), 
having a metabolism rate slower than their absorption rate, 
suffered from hyperosmolar syndromes [52]. Thus, mixtures 
of smaller doses of osmotic agents have been suggested to 
minimize the potential for adverse metabolic consequences 
while maintaining ultrafiltration [22].
This concept is supported by a randomized, 3-months 
trial in nondiabetic CAPD patients, comparing the effects 
of a PD solution with a mixture of 0.6% amino acids and 
1.4% glycerol replacing two 2.27% glucose-based conven-
tional solutions (which were used in the control group) [53]. 
Glycerol (molecular weight 92 Da) acts as an energy source 
by entering the glycolytic pathway through the Krebs cycle. 
Glycerol concentration in the experimental PD solution 
(1.4%) was lower than that used in previous studies when 
glycerol was used as the sole osmotic agent, at a high con-
centration as needed to result in an adequate fluid balance 
however putting the patient at risk of a hyperosmolar syn-
drome [54]. On the other hand, the reduced concentration of 
AA (0.6%) may allow a twice daily use of the solution, with 
AA exchange comparable to a single 1.1% amino acid daily 
exchange [22]. Clinical use of the 0.6% AA/1.4% glycerol 
PD solution proved to be safe and well tolerated, with a 
significant reduction of glucose absorption, an ultrafiltra-
tion capacity comparable to glucose, and increased dialysate 
levels of CA 125, the latter possibly indicating better pres-
ervation of mesothelial cell mass and, potentially, better 
biocompatibility [53].
In a subsequent randomized study in a rat model of 
chronic renal failure [55], daily use for 16 weeks of a bicar-
bonate/lactate-buffered solution with a mixture of osmotic 
agents (glycerol 1.4%, AA 0.5%, and dextrose 1.1%) 
(GLAD) was compared to 3.86% glucose-based solution 
and also to a buffer solution (bicarbonate/lactate-buffered 
solution without osmotic agents). Both hypertonic dialysis 
solution increased peritoneal solute transport, but GLAD 
exposure was associated with a good preservation of peri-
toneal morphology in terms of omental vessel density and 
fibrosis. It is interesting to note that results obtained with the 
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experimental solution were similar to those of bicarbonate/
lactate-buffered solution without osmotic agents [55].
Another compound which has been tested for a potential 
use in the PD solution is Taurine. Taurine (molecular weight 
125 Da) is a sulfonic beta-amino acid with high water sta-
bility that regulates osmotic balance and ion transport in 
mammalian cells where it is present in high concentration. 
In a rat PD model, Nishimura and colleagues [56] examined 
peritoneal transport and biocompatibility of a new PD solu-
tion containing taurine instead of glucose as osmotic agent. 
Net ultrafiltration of the PD-taurine solution rose in a dose-
dependent manner, and the 3.5% concentration was equiva-
lent to the 3.86% standard glucose solution. With respect 
to the peritoneal membrane, the PD-taurine solution was 
more biocompatible (lower mesothelial and fibroblast-like 
cell proliferation) than PD-glucose [56]. However, much 
caution must be taken if taurine is going to be used as an 
osmotic agent in PD. Patients with chronic kidney disease 
(CKD) are reported to be taurine depleted, with low plasma 
and intracellular concentrations of taurine [57]. Suliman 
et al. [58] have reported on an open non-randomized trial 
in 10 chronic hemodialysis patients on the effect of daily 
oral taurine substitution for 10 weeks on various neurophysi-
ological parameters as well as plasma and muscle levels of 
taurine. The dose of taurine, 100 mg/kg/day, was compara-
ble to that previously used in human clinical trials. Neuro-
logical symptoms (dizziness, non-rotatory vertigo) appeared 
in 2 out of the first 4 patients. Although these symptoms 
rapidly disappeared after stopping taurine, long-term risks 
of excessive accumulation cannot be ruled out either. The 
taurine levels in these two patients increased far above the 
normal plasma (5513% and 1780%) and muscle intracellular 
(239% and 351%) ranges.
Another osmotic agent under development is hyper-
branched polyglycerol, a polyether polymer synthesized 
by polymerization of glycidol that is highly water-soluble, 
hydrophilic, and chemically stable in aqueous solution [59].
Studies in a rat model of acute (4 h) or chronic (3 months) 
PD have shown hyperbranched polyglycerol-containing PD 
fluid, as compared to glucose-based PD solutions, may 
induce less peritoneal injury and inflammation while achiev-
ing similar ultrafiltration and waste removal [60, 61]. A more 
recent study [62] compared hyperbranched polyglycerol 
fluid to low-GDP and icodextrin PD fluid in a rat model 
(obese type 2 diabetic ZSF1 rats) of metabolic syndrome. 
At the end of the 3 months treatment period, the authors 
found that PD fluid containing hyperbranched polyglycerol 
better preserved the structures and function of the peritoneal 
membrane and kidneys, and induced less systemic adverse 
effects on metabolism, immune response and serum antioxi-
dant capacity [62]. However, caution must be taken when 
evaluating studies with icodextrin performed in rats. Garcia-
López et al. [63] studied the metabolism of icodextrin and 
alpha-amylase activity following daily exposure to dialysis 
solutions containing either glucose or icodextrin as osmotic 
agent in rats. No icodextrin could be detected in plasma, sug-
gesting that it was metabolized and excreted by the kidney 
in these non-uremic rats. In contrast to uremic peritoneal 
dialysis patients, chronic exposure to icodextrin did not seem 
to further affect alpha-amylase activity or icodextrin metabo-
lism. They concluded that the much higher alpha-amylase 
activity in plasma and dialysate in rats than in humans 
explains the much more rapid metabolism of icodextrin in 
rats compared with PD patients [63]. Results with this new 
PD solution are promising, but metabolism of polyglycerol 
in plasma and ramifications of plasma accumulation and tis-
sue disposition with long-term use remain to be precisely 
determined [4].
A recent study examined theoretically and experimen-
tally in rabbits whether low-polydispersity glucose poly-
mers could have advantages over icodextrin for long-dwell 
exchange in PD [64]. Icodextrin is a mixture of glucose 
polymers with a polydispersity (ratio of weight-average to 
number-average molecular weight) of approximately 2.6, 
and previous studies had indicated that monodisperse poly-
mers with molecular weight between 2 and 20 kDa might 
achieve a higher ultrafiltration than icodextrin [65]. Findings 
of the study show that compared to a 7.5% icodextrin solu-
tion, a PD solution containing 11% glucose polymers with a 
molecular weight of 18–19 kDa and a polydispersity of 2.0 
can generate a higher ultrafiltration without any increase in 
carbohydrate absorption [64].
The “Osmo‑Metabolic” approach to PD 
solutions
Patients suffering from ESRD may benefit locally and sys-
temically from a glucose-sparing approach, in terms of the 
PD solutions prescription [22]. Glucose-sparing strategies so 
far described are based on the use of glucose-free PD fluid, 
in order to reduce patient’s glucose exposure.
A novel and tantalizing tool to antagonize glucose-associ-
ated toxicity is represented by use of osmo-metabolic agents 
in the PD fluid. We define as osmo-metabolites those sub-
stances which exhibit both osmotically and metabolically 
favorable properties [25, 66]. This approach would ensure 
glucose-sparing not only by reducing intraperitoneal glucose 
exposure without compromising ultrafiltration, but also by 
the independent mitigation of underlying systemic nega-
tive metabolic effects caused by the glucose load, a sort of 
bioactive glucose sparing. Osmo-metabolic agents can be 
used alone, or in combination to maximize their therapeutic 
effects. Two such candidate agents are represented by l-car-
nitine and xylitol. In the following section, we review the 
available evidence for the use of l-carnitine and/or xylitol 
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in PD fluid as a new glucose-sparing strategy. In order to 
appreciate the metabolic contribution that these molecules 
make to the overall condition of the PD patient, it is nec-
essary to describe some basic features of the biochemical 
mechanisms that underlie their metabolic function.
l‑Carnitine
Biological features
l-Carnitine (molecular weight 161.2  Da) is a naturally 
occurring compound known to be essential for fatty acid 
oxidation in the mitochondria [67] (Fig. 1). It is highly water 
soluble and chemically stable in aqueous solutions in both 
acidic and basic conditions. l-Carnitine binds acyl groups 
via ester bonds with carboxylic acids at its 3-hydroxyl posi-
tion, thus serving as a ‘’carrier” for fatty acid moieties.
l-carnitine and acylcarnitine content is high set in muscle 
and liver, with a total content in the human body of about 
300 mg/Kg, of which more than 95% is intracellular. l-carni-
tine can be synthesised from the essential amino acid lysine 
and methionine, though the average adult diet provides about 
75% of daily carnitine requirements [67]. In healthy adults, 
the plasma concentration of total l-carnitine is in the range 
of 25–50 μM while the plasma level of acetyl-carnitine is 
3–6 μM. Approximately, 98–99% of the circulating l-car-
nitine filtered by the glomerulus undergoes tubular reab-
sorption with a threshold concentration of about 40–60 μM 
[68]. Thus, in subjects with normal renal function exogenous 
administration of l-carnitine raises its renal clearance, to 
maintain a plasma concentration of about 50 μM [68].
l-carnitine is taken up by cells mostly due to the organic 
cation transporter-2 (OCTN2) present into the plasma mem-
brane [69]. Loss of function mutation of OCTN2 causes a 
remarkable reduction of the uptake of L-carnitine into the 
cells and decreased intracellular l-carnitine concentration 
in the affected tissues, including liver, skeletal muscle and 
heart, a rare and severe pathological condition known as 
primary carnitine deficiency (PCD) [69].
A key partner of l-carnitine is a family of acyltrans-
ferases able to catalyse the reversible transfer of acyl groups 
between coenzyme A and l-carnitine [70]. In mammals, dif-
ferent l-carnitine acyltransferases show typical subcellular 
location and substrate preference for specific chain-length 
acyl-CoA esters.
Metabolic features of l‑carnitine relevant to PD 
therapy
As discussed above, one of the main limitations of PD ther-
apy is the poor global (local + systemic) biocompatibility of 
glucose, the most common osmotic agent used nowadays. 
Thus, reducing glucose exposure would not only spare the 
peritoneal membrane of its potential deleterious effects, 
but it would also attenuate the adverse systemic actions of 
glucose. In this regard, the use of l-carnitine as an osmo-
metabolic agent/additive may also be envisioned taking into 
account its metabolic role exerted through a mode of action 
as a conditional vitamin and/or conditional drug.
l-Carnitine as a Conditional vitamin The concept of 
l-carnitine being a conditional vitamin stems from to the 
fact that under certain disease states its requirement may 
exceed dietary intake and/or endogenous synthesis. Except 
for the rare PCD, some controversy and misconceptions exist 
regarding the presence of a similar phenotype in secondary 
carnitine deficiency (SCD). SCD can be caused by increased 
losses due to a variety of different conditions, including 
patients in HD and peritoneal dialysis [70, 71].
Fig. 1  Main metabolic function 
of the carnitine system. ACS 
acyl-CoA synthetase, CPT1 
carnitine palmitoyltransferase 
1, CPT2 carnitine palmitoyl-
transferase 2, CACT carnitine-
acylcarnitine translocase, CAT 
carnitine acetyltransferase
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Heterozygous carriers of the OCTN2 loss of function 
mutation show a 50% reduction of carnitine transport activ-
ity in fibroblasts and show a moderate reduction of plasma 
carnitine content comparable to subjects affected by SCD 
[72]. Although heterozygous carriers are thought to be 
asymptomatic, ageing and additive cardiac risk factors may 
precipitate cardiac dysfunction, left ventricular hypertrophy 
and arrhythmias. Indeed, experimental studies in heterozy-
gous rodents have shown that the incidence of cardiomyopa-
thy increases with ageing, the risk for cardiac abnormalities 
and with reduced survival when additional cardiac burdens 
are imposed [73, 74].
A genetic epidemiological study in Japan showed that 
the prevalence of heterozygotes for SLC22A5 mutations in 
OCTN2 was 1.01%, and echocardiography revealed that they 
were susceptible to late onset benign cardiac hypertrophy 
(odds ratio 15.1, 95% CI 1.39–1.64) compared with wild 
types [75]. In addition, heterozygosity for PCD mutations 
has been linked to cardiac arrhythmias that resolve after car-
nitine treatment [76].
Similar findings were obtained in murine models of mod-
erate carnitine deficiency induced with carnitine depleting 
agents such as pivalic acid, mildronate and d-carnitine 
[77–79]. We have shown that rats exposed to a moderate 
reduction in cardiac l-carnitine content are more susceptible 
to myocardial injury induced by β-adrenergic stimulation 
(isoproterenol) along with an unanticipated high mortal-
ity rate [77]. When carnitine deficiency was corrected by 
supplementing the pivalate-treated rats with l-carnitine, the 
observed detrimental effects of isoproterenol were negligible 
along with no mortality. A similar outcome was observed in 
pressure overload-induced cardiomyopathy in heterozygous 
carrier mice of OCTN2 mutation with a moderate l-carni-
tine deficiency [74]. Indeed, l-carnitine supplementation of 
such l-carnitine deficient mice subjected to ascending aortic 
constriction not only prevented cardiac injury, but it also 
increased survival rate compared to untreated mice. A mod-
erate heart carnitine deficiency induced by d-carnitine treat-
ment increased sensitivity to bupivacaine-induced asystole, 
whereas l-carnitine repletion completely reversed such effect 
[78]. This experimental study was conducted by the same 
authors after they experienced a case of peri-operative car-
diac arrest in a carnitine deficient child (valproate-induced) 
in the context of intravascular administration of bupivacaine, 
an anaesthetic known to exert cardiotoxic side effects [78]. 
Moreover, Roussel et al. were able to reproduce electrophys-
iological and structural abnormalities observed in patients 
affected by PCD by inducing a 50% reduction of l-carnitine 
plasma levels in mice exposed to MET88, a competitor 
inhibitor of OCTN2 [79]. The authors, therefore, suggest 
that in the presence of short QT syndrome or unexplained 
cardiac arrhythmias, leading to cardiac arrest even in adult 
people, carnitine deficiency must be suspected. Altogether, 
these studies clearly indicate that although a modest reduc-
tion of carnitine content in either heterozygous carrier of 
PCD or SCD may be considered a benign condition not 
necessarily associated to a pathological phenotype, the 
superimposition of an additional insult may lead to severe 
pathological consequences. Therefore, a conditional vitamin 
action of l-carnitine in PD patients could be envisioned as a 
prophylactic measure to ameliorate the above consequences.
l-Carnitine as a Conditional drug. The concept of 
l-carnitine being a conditional drug, instead, stems from the 
possibility of overexposing metabolic carnitine target organs 
to high levels of carnitine. The well-known metabolic roles 
of carnitine derive from its involvement in fatty acid oxida-
tion in the mitochondria binding acyl groups via ester bonds 
with carboxylic acids at its 3-hydroxyl position, to serve 
as a carrier for fatty acids [67]. Therefore, a key partner of 
l-carnitine is a family of acyltransferases able to catalyse the 
reversible transfer of acyl groups between coenzyme A and 
l-carnitine [70]. Because these carnitine acyltransferases 
catalyse primarily equilibrium reactions, they are important 
in modulating, and responding to, changes in the concentra-
tions of acyl-CoA esters within the cellular compartments 
in which they occur. Consequently, it is possible to alter 
acyl-CoA levels in tissues by overexposing the metabolic 
carnitine target organs to high levels of carnitine.
Whereas 98–99% of the filtered l-carnitine in the kid-
ney undergoes tubular reabsorption under normal plasma 
concentrations, at concentrations higher than 40–60 µM 
renal excretion is highly increased; thus, preventing signifi-
cant elevations in plasma l-carnitine level after exogenous 
administration either orally or intravenously [68]. In ESRD 
patients the exogenous administration of l-carnitine via a 
suitable systemic route (e.g. peritoneal dialysis) results in 
remarkable l-carnitine plasma overexposure proportional to 
the amount administered.
l-Carnitine overexposure is also expected to be present in 
organs like skeletal muscle and liver at high concentration. 
An indirect confirmation that this is the case is the remark-
able elevation of plasma acetyl-carnitine levels following 
the administration of free l-carnitine in PD patients [80]. 
The presence in mitochondria of the equilibrium enzyme 
CrAT, increases acetyl-carnitine production at the expenses 
of acetyl-CoA, due to a mass-action effect driven by the 
increased l-carnitine concentration. Therefore, the possibil-
ity to modulate the intra-mitochondrial acetyl-CoA pool by 
overexposure of tissues to carnitine, may have favourable 
metabolic consequences toward glucose and lipid homeo-
stasis in insulin resistance and diabetic patients, because 
acetyl-CoA plays a key role in the regulation of several 
important cellular functions such as gluconeogenesis, glu-
cose oxidation, protein acetylation, and steroid and fatty acid 
biosynthesis. In particular, acetyl-CoA acts as an allosteric 
activator of pyruvate dehydrogenase (PDH) kinase, which 
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phosphorylates and inhibits the alpha subunit of PDH, the 
enzyme complex that couples glycolysis to glucose oxida-
tion. Therefore, any intervention aimed to keep in a more 
active state PDH activity (i.e. inhibition of PDH kinase) 
should, in principle, favour glucose oxidation which in cer-
tain conditions (e.g. relative cardiac ischemia) may provide 
a more efficient use of substrate for energy formation in the 
heart. Experimentally, an increased muscle glucose uptake/
disposal was found in various in vitro and in vivo studies 
in non-diabetic and diabetic humans and animal models 
[68, 80–83]. Another key role of the modulation of intra-
mitochondrial acetyl-CoA by carnitine in liver regards the 
activation of pyruvate carboxylation (PC), a pivotal enzyme 
in gluconeogenesis [84]. Therefore, a reduction of the mito-
chondrial acetyl-CoA pool size by raised carnitine levels in 
liver mitochondria will lead to a less active PC, which in 
turn will significantly reduce gluconeogenetic flux.
Another possible metabolic advantage of overexposure of 
tissues to carnitine is the promotion of autophagy. Acetyl-
CoA plays a prominent role in controlling longevity and 
autophagy [85]. The involvement of acetyl-CoA in these key 
processes is based on its ability to acetylate protein lysine 
residues in various subcellular compartments, including 
mitochondria. In addition, a recent study has shown that the 
specific ablation of muscle CrAT increased tissue acetyl-
CoA levels and, consequently, the acetylation of many mito-
chondrial proteins along with an alteration of both glucose 
and insulin tolerances [86]. Therefore, a pharmacologically 
mediated excess of carnitine may moderate protein acetyla-
tion by shifting the position of the reaction catalysed by 
CrAT toward acetyl-carnitine.
Use of l‑carnitine in PD fluid
Biocompatibility profile Studies in vitro and in vivo (PD 
rabbit model) showed PD solution containing carnitine to 
be more biocompatible than standard glucose solutions and 
those containing icodextrin, in terms of mesothelial and vas-
cular changes [87]. Addition of l-carnitine to glucose-based 
PD solutions significantly improved the viability of cultured 
murine fibroblast L929 [88], a standard toxicity test, sug-
gesting a potentially protective role. Furthermore, addition 
of l-carnitine to cultured human umbilical vein endothelial 
cells (HUVECs), significantly improved cell viability, did 
not affect the percentage of early apoptotic cells, and pre-
vented glucose-induced apoptosis [88].
Osmotic capacity Studies in animal models (rat, mouse) 
of PD have shown that equi-osmolar solutions of glucose 
and l-carnitine result in a comparable amount of net peri-
toneal ultrafiltration [88]. The capacity of l-carnitine for 
ultrafiltration across the peritoneum is supported by our 
results in four stable CAPD patients receiving, over five 
consecutive days, for the long-dwell night exchanges PD 
solution containing glucose 1.5% plus l-carnitine 0.25% 
instead of a 2.5% glucose-based PD solution. Use of the 
experimental solution was well tolerated and associated 
with equivalent or possibly slightly higher net ultrafiltra-
tion than that achieved with 2.5% glucose PD solutions, 
despite the lower osmolarity of the carnitine-containing 
PD solution [88].
The function of the peritoneal membrane has been well 
described by the three-pore model, according to which the 
major transport barrier of the membrane is the capillary 
endothelium, which contains small, large, and ultra-small 
pores [89]. This predicts that about 60% of the peritoneal 
ultrafiltration induced by glucose occurs through the small 
intercellular pores, and 40% via the transcellular aqua-
porin-1, the molecular counterpart of ultra-small pores [90]. 
A similar fluid transport can be expected with l-carnitine, 
though with a little less ultrafiltration via the small pore 
pathway (since l-carnitine is slightly smaller than glucose) 
but identical water movement across aquaporins. Indeed, 
studies in a mouse knockout model for aquaporin-1 demon-
strated that approximately 50% of the ultrafiltration gener-
ated by either l-carnitine or glucose contained in the PD 
fluid reflects facilitated water transport through the ultra-
small pores [88]. Notably, l-carnitine significantly increased 
aquaporin-1 protein expression in HUVECs, and signifi-
cantly reversed the inhibitory effect of glucose on aqua-
porin-1 protein levels [88].
Metabolic effects Short-term clinical studies performed in 
CAPD patients indicated the possible, safe use of l-carnitine 
added to the PD solution. In seven CAPD patients, a dose 
of 2 g of l-carnitine added to the PD fluid and administered 
during the nocturnal exchange for two months, was well tol-
erated, restoring plasma levels (normally diminished in PD 
patients) of l-carnitine, and ameliorating the lipid pattern in 
six patients [Bazzato G, personal communication, 1981]. In 
a clinical trial on five CAPD patients who received 20 mg/
kg l-carnitine in the first daily PD solution for a period of 
14 days, an improvement in nitrogen balance and a good 
tolerability were found [Kopple JD, personal communica-
tion, 1999].
More recently, we examined in a prospective, multi-
center, parallel randomised controlled trial the effects of 
an l-carnitine-containing PD solution [80]. Nondiabetic 
ESRD patients on CAPD were randomly assigned to receive 
4 months of diurnal exchanges with either a standard glu-
cose-based solution or a solution with identical glucose 
concentrations enriched with l-carnitine (2 g in each daily 
bag), the nocturnal exchange in both groups being icodex-
trin. The primary end-point was change in insulin sensitiv-
ity, evaluated by performing a euglycemic hyperinsulinemic 
clamp. Insulin resistance is often associated with ESRD and 
may cause enhanced morbidity and mortality through an 
increased occurrence of cardiovascular disease [91].
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The presence of l-carnitine in the PD fluid was well tol-
erated by all patients, and induced a statistically significant 
increase in insulin sensitivity, as compared to both base-
line and to results obtained in the control group. In addi-
tion, a significant increase in fasting plasma insulin levels 
was found in the control, but not the intervention group. In 
the latter, plasma levels of l-carnitine markedly increased, 
achieving an apparent steady state after 30 days suggest-
ing apparent equilibrium between l-carnitine absorption, 
exposure, and excretion (drained PD fluid and urine). Supra-
physiological plasma levels of l-carnitine (> 1 mmol/L), as 
discussed above, might be behind the insulin-sensitizing 
effect of the l-carnitine-containing PD solution. At the end 
of the study period, stability in peritoneal membrane trans-
port parameters and dialysis adequacy were observed. An 
interesting observation is the significant decrease in daily 
urine output in the control group, whereas urine volume did 
not change in the intervention group. Since l-carnitine uri-
nary excretion was increased in l-carnitine-treated patients, 
this finding might be explained by an osmotically driven 
maintenance of diuresis by l-carnitine and may have clinical 
relevance since urine output in PD patients is important in 
maintaining fluid balance [92].
Xylitol
Biological features
Xylitol is a five-carbon sugar alcohol (pentitol, molecular 
weight 151.2 Da) which is synthesised by the reduction of 
d-xylulose. Based upon the daily urine excretion of l-xylu-
lose in patients with essential pentosuria [93], approximately 
5–15 g of xylitol are formed per day in the human body. 
Xylitol administered either orally or intravenously is mainly 
removed by the liver, which is responsible for 50–80% of 
xylitol metabolism in normal conditions. Extra-hepatic 
metabolism in the kidney, lung, erythrocyte, fat stores and 
myocardium can account for about 15–20% of the remaining 
proportion of parenterally administered xylitol [93, 94]. The 
clearance of xylitol from blood appeared to be a first-order 
kinetic process with a half-life of 19–23 min for non-adapted 
human adults, whereas its excretion is by simple glomeru-
lar filtration in the absence of any re-adsorptive mechanism 
[93].
On entry into the cell, xylitol is first oxidized by the 
NAD-xylitol dehydrogenase to d-xylulose, causing the 
NADH/NAD ratio to increase [93, 94] (Fig. 2). Subse-
quently, the d-xylulose-kinase phosphorylates d-xylulose 
to d-xylulose-5-phosphate. The latter is an intermediate of 
the pentose monophosphate shunt and it is metabolized to 
fructose-6-phosphate and glyceraldehyde phosphate. Con-
sequently, most of the xylitol is rapidly converted to glucose 
and glycogen, and only small quantities are converted to 
lactate (Fig. 2).
Metabolic features of Xylitol relevant to PD therapy
Xylitol is an approved compound in Germany as a sugar 
substitute of glucose in parenteral nutrition (i.e., Aminomix 
4, Fresenius Kabi; Nutriflex Combi, BBraun) and the Min-
istry of Health authorized a maximal dose of xylitol of 3 g/
kg/day. Indeed, xylitol entry into cells is insulin-independent 
and it is efficiently metabolized after being intravenously 
infused with no elevation of glycemia, stimulating much 
less insulin secretion than does glucose [95]. Since 1970, 
Fig. 2  Metabolism of d-xylitol. 
Thank to the presence of 
a NAD-dependent xylitol 
dehydrogenase, d-xylitol is 
first oxidized to d-xylulose 
and then phosphorylated to 
D-xylulose-5-phosphate by 
a d-xylulose-kinase. The lat-
ter phosphorylated product 
represents the entrance point to 
the non-oxidative branch of the 
pentose phosphate shunt, the 
main metabolic fate of d-xylitol
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it has been used in diabetics and for parenteral nutrition, 
as a glucose substitute in critically ill patients (i.e., post-
traumatic, septic patients), though in most cases xylitol has 
been administered in combination with other sugars such 
as glucose and fructose [93]. An improved glucose homeo-
stasis was observed with hypocaloric xylitol and the mix-
ture of glucose/xylitol (1:1) in animal as well as in human 
studies [96]. The nitrogen sparing properties of xylitol were 
observed in surgical intensive care patients. Hepatic glu-
coneogenesis was significantly reduced when compared to 
isocaloric glucose during xylitol infusion after trauma and 
in septic patients. In a more recent case control study, inten-
sive care patients treated for 24 h with a parenteral nutrition 
product containing only xylitol received significantly less 
insulin than patients treated with parenteral nutrition prod-
ucts not containing xylitol [97].
In a rat animal model of non-esterified fatty acid (NEFA)-
induced insulin resistance, Kishore et al. examined the effect 
of parenteral xylitol infusion during a euglycemic hyperin-
sulinemic clamp [98]. Elevated NEFA contribute to insulin 
resistance in humans through such mechanisms as down-
regulation of insulin-signaling, resulting in impaired periph-
eral glucose uptake and glycogen synthesis. Xylitol infusion 
during insulin clamp studies in normal rats prevented fatty-
acid-induced insulin resistance, with favourable effects on 
glycogen synthesis and insulin-mediated glucose uptake.
The potential favourable effects of exogenous xylitol 
administration on glucose homeostasis may be explained by 
known aspects of xylitol metabolism. For example, the gly-
caemic index of xylitol is much lower than that of glucose, 
a property that makes it more favourable if the caloric load 
needs to be better controlled, as in PD patients. Importantly, 
in human xylitol is a very poor insulin-secretagogue com-
pared to glucose [95]. Indeed, it is well known that hyperin-
sulinemia per se is probably one of the most potent drivers 
of insulin resistance [99, 100] and that a constant peritoneal 
daily glucose load may facilitate hyperinsulinemia in PD 
patients. On the other hand, it has been shown both in animal 
models and humans that insulin resistance and diabetes may 
be efficiently counteracted by K-ATP channel openers, like 
diazoxide, which inhibits β-cell insulin secretion [99].
As mentioned above, a key intermediate of liver xylitol 
metabolism is d-xylulose-5-phosphate (Xy-5-P), a com-
pound that affects the concentration of fructose 2,6-bispho-
sphate (F 2,6-P2), the most potent activator of phosphof-
ructokinase and hence glycolysis, especially in liver [101]. 
Synthesis and degradation of F2,6-P2 are catalysed by a 
bifunctional enzyme, Fru-6-P,2-kinase: Fru-2,6-bisphos-
phatase, which in turn is regulated by a cAMP-dependent 
protein kinase and a protein phosphatase 2A. When the 
kinase is activated, gluconeogenesis is stimulated via a 
decrease of F 2,6-P2, whereas the phosphatase is activated 
to stimulate glycolysis via an increase of F 2,6-P. Since 
Xy-5-P is an allosteric activator of protein phosphatase 
2A, this results in a rapid increase in F 2,6-P2, activation 
of phosphofructokinase, thus activating glycolysis, and 
inhibiting gluconeogenesis [102]. This is consistent with 
the observation that the infusion of xylitol during a com-
bination of a pancreatic and hyperglycemic clamp leads to 
a significant elevation of Xy-5-P. Interestingly, xylitol also 
induces a marked decrease of phosphonelpyruvic carboxyki-
nase (PEPCK) mRNA in the liver, suggesting that Xy-5-P 
may also depress gluconeogenesis via a direct transcriptional 
effect [103].
Use of Xylitol in PD solution
Biocompatibility profile The biocompatibility and toxicity 
of a PD solution containing d-xylitol in different concen-
trations compared to glucose was examined in mesothelial 
cells in vitro [Arduini A, Patent PCT/EP2006/060162]. Main 
findings were: an increase in the number of mesothelial cells 
in the presence of solutions with low or absent glucose; 
higher concentrations of phospholipids and phosphatidyl-
choline (indispensable surfactants for normal functioning 
peritoneum) in the presence of d-xylitol; lower formation 
of giant cells and no increase in interleukin 1 (expression of 
cellular injury) with PD fluid containing xylitol.
Osmotic capacity. Although data for d-xylitol are scanty 
compared to those for l-carnitine, fluid transport across 
peritoneum comparable to l-carnitine is likely given the 
closeness of their molecular weight. In a clinical trial many 
years ago [104], six insulin-dependent diabetic patients 
on CAPD were switched from a glucose-based PD regi-
men to a daily therapeutic program consisting of the use of 
d-xylitol as the sole osmotic agent (three daily exchanges 
of PD solution with xylitol 1.5% and one exchange with 
xylitol 3%). After a follow-up of five months, fluid balance 
(as indicated by peritoneal ultrafiltration, body weight, and 
mean arterial pressure) obtained with xylitol-containing 
PD solution was comparable to that obtained with glucose 
use [104]. Metabolic effects In the clinical trial conducted 
by Bazzato et  al. in ESRD insulin-dependent diabetics 
on CAPD [104], the therapeutic schedule, followed for a 
median duration of 8.7 months (range 5–11 months), con-
sisted in 4 daily exchanges of 2L PD solution, from which 
3 were with normal osmolality solution (xylitol 1.5 g/dL) 
and one with hyperosmolar solution (3 g/dL). The total 
daily dose of xylitol administered via peritoneum with this 
protocol was 150 g. The plasma xylitol level was 30 mg/
dL during the daily dwells and reached 80 mg/dL during 
the nocturnal dwell. These concentrations had no influence 
on plasma osmolality. The required exogenous insulin was 
reduced by 50% compared to the amount administered dur-
ing CAPD with glucose. HbA1c was significantly lower dur-
ing treatment with xylitol as compared to the therapeutic 
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period with glucose, indicating better glycemic control in 
diabetic patients [104]. It should be noted that the extent of 
the improvement of glycemic control in the CAPD patients 
treated with xylitol was remarkable (from 12.99 to 10.72% 
HbA1C) and cannot be solely explained by glucose-sparing 
action. Indeed, as discussed above, xylitol metabolic by-
product like Xy-5-P is a potent allosteric and transcriptional 
activator favourably affecting liver glucose homeostasis in 
insulin resistance and diabetes (see above).
In treated patients there was a significant improvement 
in the lipid profile: triglycerides and total cholesterol lev-
els decreased after the first two months of treatment, while 
HDL-cholesterol increased, restoring normal levels after 
2–5 months. All these parameters remained stable in the 
month subsequent to the study. The plasma concentration 
of inorganic phosphorus, compromised during CAPD with 
glucose, was restored in months of treatment. During the 
observation period, a progressive increase of serum uric 
acid concentration was found in PD patients treated with 
PD solution containing xylitol, requiring administration of 
allopurinol that induced a slow reduction of these values 
[104]. Lactic acid was also enhanced during the entire treat-
ment period, remaining however within normal range. The 
dosage of 150 g/day xylitol was well tolerated, without evi-
dences of adverse effects or clinical signs of calcium oxalate 
deposition. Only when the xylitol dosage exceeded 150 g/
day, in patients who needed PD solutions with higher con-
tent of xylitol in order to augment the ultrafiltration effect, 
adverse events like nausea, vomiting or increased levels of 
serum bilirubin and transaminases occurred [104].
The use of xylitol as partial substitute of glucose in peri-
toneal dialysis bags was more recently examined by employ-
ing a 2.5% (w/v) xylitol-based PD solution for the long-
dwell (nocturnal) exchange, with 50 g of instilled xylitol 
(Buoncristiani U, personal communication, 2004). The ben-
eficial effects of xylitol-based PD solution were a lower 24-h 
glycemic curve and a reduced response of insulin. Moreover, 
the lipid metabolism seemed to be improved and an increase 
of serum protein and albumin was found. Two patients have 
used such xylitol-based PD solution for 10 years and only 
a slight increase in serum uric acid levels, which however 
remained within normal range, was observed (Buoncristiani 
U, personal communication, 2004).
Combining l‑carnitine and Xylitol in PD fluid
The concept of introducing more than one osmo-metabolic 
agent to dialysate is derived from the approach of polyphar-
macy or combination therapy, whereby the aim is to achieve 
a favorable synergetic action. We have recently examined the 
biocompatibility of a new solution containing l-carnitine 
(1.24 mmol/L), xylitol (46 or 98.8 mmol/L), and low-dose 
glucose (27.7  mmol/L) [66]. Maximum xylitol dosage 
patients would be exposed to is 36 g/day, similar or lesser 
than that used by Buoncristiani (50 g/day), and much less 
than that used by Bazzato (150 g/day) [104].
The new solution was compared to low-GDPs glucose-
based PD solution and tested in cultured HUVECs obtained 
from the umbilical cords of healthy and gestational diabetic 
mothers. Gestational diabetes is associated with inflam-
mation, oxidative stress, and overexpression of inflamma-
tory cytokines, which represent common abnormalities in 
patients on PD. In both endothelial cell types, the use of 
experimental PD solution did not change the proliferative 
potential and significantly improved cell viability. Glu-
cose-based solutions significantly increased the membrane 
expression of Intracellular Adhesion Molecule-1 (ICAM-
1) and Vascular Adhesion Molecule-1 (VCAM-1). Such 
pro-inflammatory vascular effect may promote adhesion of 
monocytes to endothelial cells, a crucial event in the early 
atherosclerotic process [105]. Indeed, a significant increase 
in monocyte interaction with HUVECs was found with glu-
cose-based PD fluids [66]. All such unfavorable vascular 
effects were absent when endothelial cells were exposed to 
the experimental PD solution. To be noted that, although the 
test solution contained some glucose, it was at a lower con-
centration and did not seem to have the deleterious effects 
the higher concentration did. Thus, a small amount of glu-
cose may be maintained in the formulation of the PD solu-
tion, in order to take advantage of its ultrafiltration ability 
and energy-providing potential.
Two clinical trials with new PDSs based on l-carnitine, 
xylitol, and low glucose are under advanced development. 
FIRST (efficacy and saFety assessments of a peritoneal dIal-
ysis solution containing glucose, xylitol and l-CarRnitine 
compared to standard PD SoluTions in CAPD) is an ongoing 
1-month study designed to evaluate safety, tolerability, and 
efficacy of the proposed new PD solution (NCT04001036). 
The ELIXIR trial (a study to EvaLuate the effIcacy and 
safety of Xylocore, a glucose sparing expeRimental solution 
for PD) is a randomized, controlled, parallel groups, interna-
tional multicenter study, whose primary objective is the non-
inferiority of the experimental solution compared to a glu-
cose-based low-GDP PD solution with regard to safety and 
efficacy, over a 6-month treatment period (NCT03994471).
Conclusions
The limitations of the currently available glucose-based 
solutions for PD are widely recognized. Exposure to sig-
nificant amounts of glucose during the course of PD is of 
concern for both local and systemic detrimental effects [22], 
and it is thought that glucose sparing should mitigate these 
effects [4].
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An ideal biocompatible solution for PD should deliver 
prolonged and sustained ultrafiltration and solute clearance, 
not influence the normal peritoneal morphology and physiol-
ogy, not induce systemic adverse effects related to absorp-
tion, and, last but not least important, provide beneficial 
metabolic and nutritional effects, if absorbed.
The two main forms of PD have some peculiar differ-
ences: CAPD (manual) composes of 4–5 exchanges with 
long dwell times around the day, whereas APD (automated) 
is usually performed during the night (8–10 h duration) with 
short dwell time cycles, which can be “extended” with one 
or two long dwell during the rest of the day (14–16 h dura-
tion). It should also be taken into account that PD solutions 
using osmo-metabolic agents, capable to reduce glucose 
exposure and/or attenuate its systemic effect, may have dif-
ferent impact, depending on the modality (CAPD or APD) 
and the prescription, to sustain the osmotic gradient over 
the dwell time the peritoneal cavity is exposed to the PD 
solution. Likewise, any PD treatment aimed to reduce, 
among others, glucose exposure may further benefit in using 
osmo-metabolic agents. This is the case of incremental PD, 
a dialysis strategy that is in keeping with the issue of green 
nephrology [106], and may offer several advantages with no 
evidence of any harmful effect [107, 108].
Data reviewed in this article suggest that a PD solution 
containing osmo-metabolic agent, besides lower concen-
trations of glucose when compared to the glucose-based 
present PD solutions, may not only significantly decrease 
the amount of glucose currently present in commercial PD 
solutions, but also take advantage of the described metabolic 
properties, and correct potential metabolic deficiencies or 
abnormalities.
l-carnitine and d-xylitol are two concrete examples of 
such agents (Fig. 3); a synergistic effect by the two com-
pounds in terms of improving glucose and lipid homeo-
stasis in PD patients can be anticipated, and this in turn 
may significantly attenuate cardiovascular morbidity in 
both diabetic and non-diabetic patients on PD therapy. The 
d-xylitol-d-glucose-l-Carnitine-based PD solution is also 
characterized by a more biocompatible profile than d-glu-
cose-based ones [66].
It is essential to address another important outcome 
aspect: the cost-benefits of the PD solutions in the market. 
While the “established glucose-sparing PD solutions” (ico-
dextrin, amino acids) are widely used in the developed world 
with both clinical as health economic proven benefits to the 
patients and the society, most of the countries in develop-
ment have either a very limited or no access at all to these 
glucose-sparing PD solutions, due to their cost. Another 
benefit of the osmo-metabolic approach could be that these 
“newcomer” PD solutions, besides showing their competi-
tive potential in regard to efficiency, effectivity, clinical and 
safety aspects, they might also broaden the offer in relation 
to the demand.
Osmo-metabolic agents can be used alone, or in combina-
tion, to maximize their therapeutic effects. The results of the 
FIRST and ELIXIR studies will clarify whether the osmo-
metabolic agents approach promising results are borne out 
in large randomized studies. Future research should also be 
directed to the identification of additional osmo-metabolic 
Fig. 3  Potential benefits of the 
osmo-metabolic approach in 
PD fluid
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agents and how to combine them to better address not only 
preservation of peritoneal membrane and residual kidney 
functions, but also underlying comorbidities able to increase 
cardiovascular risk.
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